Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet

128
25
Favorite

Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet

Tiger Newspress2021-08-02

(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.

"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial," said Andrei Floroiu, CEO of Vaxart.

The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.

Vaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

128

Report

Comment（25）

Kaboom
·2021-08-03
What’s IND?
Reply
1
Report
ASMH
·2021-08-03
Like
Reply
2
Report
Fold Replies
- ASMH:
  Like
  2021-08-11
  Reply
  Report
- Loola:
  like
  2021-08-10
  Reply
  Report
- ASMH:
  Like
  2021-08-04
  Reply
  Report
View more 1 comments
Astlen
·2021-08-03
Cool
Reply
1
Report
晓MIIN
·2021-08-03
?
Reply
3
Report
Esha
·2021-08-03
Good jump. ???
Reply
2
Report
YYKTAN
·2021-08-03
Like pls
Reply
5
Report
tianzi
·2021-08-03
Nice sharing
Reply
2
Report
Jasmineding
·2021-08-03
Good
Reply
1
Report
Kennypang92
·2021-08-03
Ok
Reply
3
Report
AmosOng
·2021-08-02
Nice
Reply
4
Report
OO_898
·2021-08-02
Like
Reply
7
Report
MrGuHHH
·2021-08-02
ok
Reply
4
Report
Fold Replies
- Benedict_cyh:
  N
  2021-08-03
  Reply
  Report
markkk
·2021-08-02
nice
Reply
3
Report
PanaCota
·2021-08-02
Ok
Reply
3
Report
PanaCota
·2021-08-02
Ok
Reply
3
Report
KailashN
·2021-08-02
Good! Like please
Reply
4
Report
Redevilz
·2021-08-02
Go higher please
Reply
5
Report
Fold Replies
- Cyberboyz:
  Yeah
  2021-08-04
  Reply
  Report
Money99
·2021-08-02
Good
Reply
6
Report
Fold Replies
- Cyberboyz:
  Yes
  2021-08-04
  Reply
  Report
blackmetal
·2021-08-02
Leave one comment
Reply
3
Report
Fold Replies
- El888:
  Same
  2021-08-02
  Reply
  Report
- KailashN:
  Done
  2021-08-02
  Reply
  Report
- markkk:
  bice
  2021-08-02
  Reply
  Report
aiyohyun
·2021-08-02
Ok
Reply
3
Report
Fold Replies
- aiyohyun:
  ok
  2021-08-02
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1164080452?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-08-02 22:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164080452","market":"us","top_or_hot":-1,"title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","media":"Tiger Newspress","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n2021-08-02 22:38 北京时间&nbsp;&nbsp;&nbsp;<strong>Tiger Newspress</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VXRT","symbol_name":"Vaxart, Inc","start_time":0,"source_url":null,"article_id":"1164080452","we_media_id":"1079075236","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","pubTimestamp":1627915085,"sourceInfo":null,"weMediaInfo":{"media_name":"Tiger Newspress","introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VXRT":"Vaxart, Inc"},"translate_title":"美国食品和药物管理局批准口服新冠肺炎疫苗片剂后，Vaxart股价上涨超过8%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXRT":0.9},"content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","kind":null,"is_publish_news":false,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":807357178,"gmtCreate":1628002222894,"gmtModify":1703499496118,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3573515033218465","authorIdStr":"3573515033218465"},"htmlText":"What’s IND?","listText":"What’s IND?","text":"What’s IND?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/807357178","repostId":1164080452,"repostType":2,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://ttm.financial/m/news/1164080452?lang=&edition=fundamental","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804173208,"gmtCreate":1627947986004,"gmtModify":1703498240612,"author":{"id":"3586939439858903","authorId":"3586939439858903","name":"ASMH","avatar":"https://static.tigerbbs.com/c8c22c3127769d9bb7b4e8d291d98433","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586939439858903","authorIdStr":"3586939439858903"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/804173208","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://ttm.financial/m/news/1164080452?lang=&edition=fundamental","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5487592,"gmtCreate":1628637348194,"gmtModify":1663232195838,"authorId":3586939439858903,"author":{"id":3586939439858903,"idStr":"3586939439858903","authorId":3586939439858903,"name":"ASMH","avatar":"https://static.tigerbbs.com/c8c22c3127769d9bb7b4e8d291d98433","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":804173208,"type":1,"supId":5483578,"prevId":0,"content":"Like","text":"Like","html":"Like"},{"id":5483578,"gmtCreate":1628597842419,"gmtModify":1663232178242,"authorId":3577872621107081,"author":{"id":3577872621107081,"idStr":"3577872621107081","authorId":3577872621107081,"name":"Loola","avatar":"https://static.tigerbbs.com/64940dfb0e60ec6f7fff49d64ddfc53a","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":804173208,"type":1,"supId":0,"prevId":0,"content":"like","text":"like","html":"like"},{"id":5419343,"gmtCreate":1628037652447,"gmtModify":1663231894040,"authorId":3586939439858903,"author":{"id":3586939439858903,"idStr":"3586939439858903","authorId":3586939439858903,"name":"ASMH","avatar":"https://static.tigerbbs.com/c8c22c3127769d9bb7b4e8d291d98433","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":804173208,"type":1,"supId":5407635,"prevId":0,"content":"Like","text":"Like","html":"Like"},{"id":5407635,"gmtCreate":1627948381235,"gmtModify":1663231842562,"authorId":3575125836760247,"author":{"id":3575125836760247,"idStr":"3575125836760247","authorId":3575125836760247,"name":"Singman","avatar":"https://static.tigerbbs.com/d770feb757705f2d631d2d5f381ae07b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":804173208,"type":1,"supId":0,"prevId":0,"content":"like too.","text":"like too.","html":"like too."}],"langContent":"EN"},{"id":804143403,"gmtCreate":1627947493802,"gmtModify":1703498226781,"author":{"id":"3585883817320380","authorId":"3585883817320380","name":"Astlen","avatar":"https://static.tigerbbs.com/74d3365b9fec276d23866d035ec56152","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3585883817320380","authorIdStr":"3585883817320380"},"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/804143403","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://ttm.financial/m/news/1164080452?lang=&edition=fundamental","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804156415,"gmtCreate":1627947238837,"gmtModify":1703498216923,"author":{"id":"3573767135380290","authorId":"3573767135380290","name":"晓MIIN","avatar":"https://static.tigerbbs.com/9e223a6a40d05afa03fb58b646e13cd1","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3573767135380290","authorIdStr":"3573767135380290"},"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/804156415","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://ttm.financial/m/news/1164080452?lang=&edition=fundamental","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804165775,"gmtCreate":1627946436097,"gmtModify":1703498191194,"author":{"id":"3578623735089935","authorId":"3578623735089935","name":"Esha","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3578623735089935","authorIdStr":"3578623735089935"},"htmlText":"Good jump. ???","listText":"Good jump. ???","text":"Good jump. ???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/804165775","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://ttm.financial/m/news/1164080452?lang=&edition=fundamental","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804184714,"gmtCreate":1627945912338,"gmtModify":1703498178160,"author":{"id":"3586858995147972","authorId":"3586858995147972","name":"YYKTAN","avatar":"https://static.tigerbbs.com/e9c7bf12299d79e1cacc0c24919b7a3c","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3586858995147972","authorIdStr":"3586858995147972"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/804184714","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://ttm.financial/m/news/1164080452?lang=&edition=fundamental","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804352826,"gmtCreate":1627939200865,"gmtModify":1703498073537,"author":{"id":"4088786948347050","authorId":"4088786948347050","name":"tianzi","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4088786948347050","authorIdStr":"4088786948347050"},"htmlText":"Nice sharing","listText":"Nice sharing","text":"Nice sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/804352826","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://ttm.financial/m/news/1164080452?lang=&edition=fundamental","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804337717,"gmtCreate":1627921180139,"gmtModify":1703498008125,"author":{"id":"3570431728680943","authorId":"3570431728680943","name":"Jasmineding","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3570431728680943","authorIdStr":"3570431728680943"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/804337717","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://ttm.financial/m/news/1164080452?lang=&edition=fundamental","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804330613,"gmtCreate":1627920441432,"gmtModify":1703497994524,"author":{"id":"4087263927700590","authorId":"4087263927700590","name":"Kennypang92","avatar":"https://static.tigerbbs.com/be100a8f75ff1601b99932f9128063af","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087263927700590","authorIdStr":"4087263927700590"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/804330613","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://ttm.financial/m/news/1164080452?lang=&edition=fundamental","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804971436,"gmtCreate":1627918595125,"gmtModify":1703497956296,"author":{"id":"4089419582580250","authorId":"4089419582580250","name":"AmosOng","avatar":"https://static.tigerbbs.com/fba31698cfe7796a86f6ea286063390f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4089419582580250","authorIdStr":"4089419582580250"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/804971436","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://ttm.financial/m/news/1164080452?lang=&edition=fundamental","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804942702,"gmtCreate":1627918271706,"gmtModify":1703497946181,"author":{"id":"3582969710070724","authorId":"3582969710070724","name":"OO_898","avatar":"https://static.tigerbbs.com/9fb3c360d5d7711641a868a144192fc7","vip":1,"crmLevel":4,"crmLevelSwitch":1,"idStr":"3582969710070724","authorIdStr":"3582969710070724"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/804942702","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://ttm.financial/m/news/1164080452?lang=&edition=fundamental","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804949545,"gmtCreate":1627917948787,"gmtModify":1703497938940,"author":{"id":"3585044989004914","authorId":"3585044989004914","name":"MrGuHHH","avatar":"https://static.tigerbbs.com/c18292278997ef02dd367e55844bf1de","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3585044989004914","authorIdStr":"3585044989004914"},"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/804949545","repostId":1164080452,"repostType":2,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://ttm.financial/m/news/1164080452?lang=&edition=fundamental","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5406182,"gmtCreate":1627927713621,"gmtModify":1663231836326,"authorId":3581667328055955,"author":{"id":3581667328055955,"idStr":"3581667328055955","authorId":3581667328055955,"name":"Benedict_cyh","avatar":"https://static.tigerbbs.com/216a5cf2e56f81472309860a063b75a6","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":804949545,"type":1,"supId":0,"prevId":0,"content":"N","text":"N","html":"N"}],"langContent":"EN"},{"id":804954011,"gmtCreate":1627917744333,"gmtModify":1703497933667,"author":{"id":"3576420733683738","authorId":"3576420733683738","name":"markkk","avatar":"https://static.tigerbbs.com/df42d8e8fb0e4c7a09fcf6592b170a1e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576420733683738","authorIdStr":"3576420733683738"},"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/804954011","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://ttm.financial/m/news/1164080452?lang=&edition=fundamental","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804951717,"gmtCreate":1627917564839,"gmtModify":1703497928073,"author":{"id":"3581588474178431","authorId":"3581588474178431","name":"PanaCota","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581588474178431","authorIdStr":"3581588474178431"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/804951717","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://ttm.financial/m/news/1164080452?lang=&edition=fundamental","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804951682,"gmtCreate":1627917555846,"gmtModify":1703497927086,"author":{"id":"3581588474178431","authorId":"3581588474178431","name":"PanaCota","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581588474178431","authorIdStr":"3581588474178431"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/804951682","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://ttm.financial/m/news/1164080452?lang=&edition=fundamental","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804926070,"gmtCreate":1627917228390,"gmtModify":1703497913366,"author":{"id":"3582703680193232","authorId":"3582703680193232","name":"KailashN","avatar":"https://static.tigerbbs.com/bcea4d0815f5091810e222c8e9e54c35","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582703680193232","authorIdStr":"3582703680193232"},"htmlText":"Good! Like please","listText":"Good! Like please","text":"Good! Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/804926070","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://ttm.financial/m/news/1164080452?lang=&edition=fundamental","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":804921906,"gmtCreate":1627917123105,"gmtModify":1703497912200,"author":{"id":"3562980680046161","authorId":"3562980680046161","name":"Redevilz","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3562980680046161","authorIdStr":"3562980680046161"},"htmlText":"Go higher please","listText":"Go higher please","text":"Go higher please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/804921906","repostId":1164080452,"repostType":2,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://ttm.financial/m/news/1164080452?lang=&edition=fundamental","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5426621,"gmtCreate":1628086906556,"gmtModify":1635160166795,"authorId":3583025625698124,"author":{"id":3583025625698124,"idStr":"3583025625698124","authorId":3583025625698124,"name":"Cyberboyz","avatar":"https://static.tigerbbs.com/bda6a2e3c6fe5eaf97f2228f49f8e497","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":804921906,"type":1,"supId":0,"prevId":0,"content":"Yeah","text":"Yeah","html":"Yeah"}],"langContent":"EN"},{"id":804989502,"gmtCreate":1627916049406,"gmtModify":1703497879090,"author":{"id":"3581545542045651","authorId":"3581545542045651","name":"Money99","avatar":"https://static.tigerbbs.com/f333c4a87fea0043f4483c465362baf9","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3581545542045651","authorIdStr":"3581545542045651"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/804989502","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://ttm.financial/m/news/1164080452?lang=&edition=fundamental","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5426622,"gmtCreate":1628086915818,"gmtModify":1663231927541,"authorId":3583025625698124,"author":{"id":3583025625698124,"idStr":"3583025625698124","authorId":3583025625698124,"name":"Cyberboyz","avatar":"https://static.tigerbbs.com/bda6a2e3c6fe5eaf97f2228f49f8e497","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":804989502,"type":1,"supId":0,"prevId":0,"content":"Yes","text":"Yes","html":"Yes"}],"langContent":"EN"},{"id":804980773,"gmtCreate":1627916011292,"gmtModify":1703497878088,"author":{"id":"3576318339568790","authorId":"3576318339568790","name":"blackmetal","avatar":"https://static.tigerbbs.com/fcf35b941f4aacd314b36e1f1d2b9bc5","vip":1,"crmLevel":9,"crmLevelSwitch":0,"idStr":"3576318339568790","authorIdStr":"3576318339568790"},"htmlText":"Leave one comment","listText":"Leave one comment","text":"Leave one comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/804980773","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://ttm.financial/m/news/1164080452?lang=&edition=fundamental","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5405286,"gmtCreate":1627917453870,"gmtModify":1663231834631,"authorId":3574042378067249,"author":{"id":3574042378067249,"idStr":"3574042378067249","authorId":3574042378067249,"name":"El888","avatar":"https://static.tigerbbs.com/9ae2260d0c9fcfaa0627f13d75da54b2","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":804980773,"type":1,"supId":0,"prevId":0,"content":"Same","text":"Same","html":"Same"},{"id":5405243,"gmtCreate":1627917271135,"gmtModify":1663231833746,"authorId":3582703680193232,"author":{"id":3582703680193232,"idStr":"3582703680193232","authorId":3582703680193232,"name":"KailashN","avatar":"https://static.tigerbbs.com/bcea4d0815f5091810e222c8e9e54c35","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":804980773,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"},{"id":5405347,"gmtCreate":1627917739413,"gmtModify":1663231832747,"authorId":3576420733683738,"author":{"id":3576420733683738,"idStr":"3576420733683738","authorId":3576420733683738,"name":"markkk","avatar":"https://static.tigerbbs.com/df42d8e8fb0e4c7a09fcf6592b170a1e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":804980773,"type":1,"supId":5405286,"prevId":0,"content":"bice","text":"bice","html":"bice"}],"langContent":"EN"},{"id":804980946,"gmtCreate":1627915950785,"gmtModify":1703497876603,"author":{"id":"3582936698066263","authorId":"3582936698066263","name":"aiyohyun","avatar":"https://static.tigerbbs.com/5efe05924fc38dd8db647c314e32c5b2","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3582936698066263","authorIdStr":"3582936698066263"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/804980946","repostId":1164080452,"repostType":4,"repost":{"id":"1164080452","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627915085,"share":"https://ttm.financial/m/news/1164080452?lang=&edition=fundamental","pubTime":"2021-08-02 22:38","market":"us","language":"en","title":"Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=1164080452","media":"Tiger Newspress","summary":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"T","content":"<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 2)&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> stock jumps over&nbsp;8% after FDA clears IND for oral COVID-19 vaccine tablet.</p>\n<p><img src=\"https://static.tigerbbs.com/c073642b8022d29863e3a55198482ab8\" tg-width=\"725\" tg-height=\"633\" referrerpolicy=\"no-referrer\">\"This is great news because it allows us to move forward with our first S-only vaccine construct.&nbsp;As we said at the end of the first quarter,&nbsp;we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\"&nbsp;said&nbsp;<b>Andrei Floroiu</b>, CEO of Vaxart.</p>\n<p>The Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.</p>\n<p>Vaxart Inc is a clinical-stage biotechnology company that focuses&nbsp;on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164080452","content_text":"(August 2) Vaxart, Inc stock jumps over 8% after FDA clears IND for oral COVID-19 vaccine tablet.\n\"This is great news because it allows us to move forward with our first S-only vaccine construct. As we said at the end of the first quarter, we will explore multiple S-only constructs in clinical trials alongside the S+N construct that has already completed its Phase I trial,\" said Andrei Floroiu, CEO of Vaxart.\nThe Phase II clinical trial with the S-only construct is expected to start in the second half of 2021.\nVaxart Inc is a clinical-stage biotechnology company that focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5405010,"gmtCreate":1627915979170,"gmtModify":1663231831127,"authorId":3582936698066263,"author":{"id":3582936698066263,"idStr":"3582936698066263","authorId":3582936698066263,"name":"aiyohyun","avatar":"https://static.tigerbbs.com/5efe05924fc38dd8db647c314e32c5b2","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":804980946,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":128,"commentSize":25,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}